Subject: AVVH Announces Product Expansion

SCV Client Spotlight
AVVH Announces Product Expansion
Hot Stock to WatchHot Stock to Watch

Company: avVaa World Health Care Products Inc. (Pink Sheets: AVVH)

End of Day:

Price: 0.0003

Change (%): + 0 (0.00)

Volume: 301,000
AVVA Chart

avVaa World Health Care Products announces product expansion to the corporate brand Neuroskin with 3 new products.

Richmond, Virginia, September 30, 2013 - avVaa World Health Care Products ("the Company") ("avVaa" or "the Company") (Pink Sheets: AVVH) AVVAA would like to announce it will be expanding its line of Neuroskin products beginning this fall with the initial introduction of 3 new products.

In its biologically active "amorphous" form, silica plays an important role in the growth and development of collagen, which in turn provides skin with firmness, elasticity and strength. Unlike other products currently on the market today containing silica ingredients, Neuroskin contains biologically active silicon dioxide. This is because the silica is broken down to a very tiny or "nano-particle" level. This patented nanotechnology allows the silica to be absorbed into the skin while maintaining its biologic properties.

Continue Reading

Top PerformerYesterday's Top Performer

Fortran Corp. (Pink Sheets: FRTN)

End of Day:

Price: 1.00

Change (%): + 0.10 (11.11)

Volume: 9,510
FRTN Chart

About Fortran Corp.

Fortran Corp., is a leading communications system integrator through it's subsidiaries, The New Telephone Company, Inc., CCI-Telecom, Inc., B & L Telephone, LLC and Fortran Communications, Inc. Fortran Corp. is dedicated to designing, sourcing, implementing and maintaining today's complex communications solutions for business and governments. Fortran services more than 3,000 clients in 2 states with 3 offices in the southeast.

Company Information Sheet

Other Small Cap News

Company: AVT, Inc. (Pink Sheets: AVTC)

AVT Given "Buy" Rating From Zacks Investment Research

Leading Investment Firm Initiates Coverage with a Buy Rating and a $2.60 Target Price

CORONA, Calif., Sept. 30, 2013 /PRNewswire/ -- AVT, Inc. (OTC Markets: AVTC), a leader in automated retailing systems, micro-stores and kiosks, has been given a "Buy" rating from Zacks Investment Research.

With revenues that have almost doubled each of the last four years, AVT has become a leading developer and supplier of innovative automated retailing systems, self-service kiosks, and micro-stores. Management's goal is to reach 100 million dollars in revenue by the end of 2015.

Continue Reading

Company: LaserLock Technologies, Inc. (OTCBB: LLTI)

LaserLock Technologies Applauds the U.S. House Passage of the Drug Quality and Security Act

WASHINGTON, Sept. 30, 2013 /PRNewswire/ -- LaserLock Technologies, Inc. (OTCBB: LLTI), a company involved in authenticating products and people, today expressed its support of the Drug Quality and Security Act passed by the U.S. House of Representatives. The bill would create a national set of standards to track pharmaceuticals through the distribution chain to help thwart the introduction of fake medication into the drug supply.

"We are pleased that the U.S. House is taking desperately needed measures to protect the American people from the threat of counterfeit pharmaceuticals and we strongly urge the Senate to do the same," said Neil Alpert, CEO of LaserLock Technologies. "We believe it is critical that government, the healthcare industry and authentication providers work together to solve this problem and our Characteristic Verification System is uniquely positioned to provide this kind of service."

Continue Reading

Market News

By Lee Brodie: CNBC

Cramer: Biggest blockbuster drug in ages?

If you're willing to speculate, Cramer wants you to know about the company behind this potential breakthrough cancer drug.

"I'm talking about Pharmacyclics (PCYC)," said Cramer, the maker of Ibrutinib ." "Currently the drug is being studied as a treatment for different types of blood cancers including chronic lymphocytic leukemia, mantle cell lymphoma, and multiple myeloma."

Results are quite promising. The clinical trial data for Ibrutinib has been very strong.

In fact results are so strong, "The Food and Drug Administration already considers Ibrutinib a breakthrough drug -that's the designation the FDA gives to drug candidates that it feels are transformational. And Ibrutinib has received this breakthrough drug designation three times over," Cramer said.

Continue Reading

By Matt Nesto:

The Upside to a Closed Government

For most of us, Tuesday will simply mark the first day of October or perhaps the start of the fourth quarter. But in Washington, October 1st is New Year's Day, as in fiscal new year, and once again, the federal government looks like it's going to be late to the party. This as lawmakers haggle and horse-trade down to the final minute, risking the closure of non-essential government offices, in hopes of securing the best possible political outcome for themselves.

While the President, the chairman of the Federal Reserve and many others are warning that such a closure would hurt an already fledgling economic recovery, not everyone agrees.

"I don't think shutting down the government can do any more destruction than a lot of what government actually does right now," says Jonathan Hoenig of, in the attached video. "Anything that can be done to slow the size and scope of government is ultimately a beneficial thing for the bottom line."

Continue Reading

Like Us on FacebookFollow Us on Twitter

SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that the information is accurate. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from You may opt out of our distribution list at any time by clicking on the "unsubscribe" link below. Link to full disclosure about compensation paid to, Inc. by companies featured on our website or in our e-mail communications.

About Penny Stocks